A citation-based method for searching scientific literature

Sehhoon Park, Beung-Chul Ahn, Sung Won Lim, Jong-Mu Sun, Hye Ryun Kim, Min Hee Hong, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Yoon La Choi, Byoung Chul Cho, Myung-Ju Ahn. J Thorac Oncol 2018
Times Cited: 54



Alice T Shaw, Enriqueta Felip, Todd M Bauer, Benjamin Besse, Alejandro Navarro, Sophie Postel-Vinay, Justin F Gainor, Melissa Johnson, Jorg Dietrich, Leonard P James, Jill S Clancy, Joseph Chen, Jean-François Martini, Antonello Abbattista, Benjamin J Solomon. Lancet Oncol 2017
Times Cited: 390




List of shared articles



Times cited

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
14


Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study.
Esther Conde, Susana Hernandez, Rebeca Martinez, Barbara Angulo, Javier De Castro, Ana Collazo-Lorduy, Beatriz Jimenez, Alfonso Muriel, Jose Luis Mate, Teresa Moran,[...]. J Thorac Oncol 2019
37


Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
12

Treatment of oncogene-driven non-small cell lung cancer.
Elisabeth A Kastelijn, Adrianus J de Langen, Bas J M Peters. Curr Opin Pulm Med 2019
6

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Real-World Management and Outcomes of Crizotinib-Treated ROS1-Rearranged NSCLC: A Retrospective Canadian Cohort.
Amanda J W Gibson, Adrian Box, Winson Y Cheung, Michelle L Dean, Anifat A Elegbede, Desiree Hao, Aliyah Pabani, Randeep Sangha, Dafydd Gwyn Bebb. Curr Oncol 2022
0

Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer.
Mi Ran Yun, Dong Hwi Kim, Seok-Young Kim, Hyeong-Seok Joo, You Won Lee, Hun Mi Choi, Chae Won Park, Seong Gu Heo, Han Na Kang, Sung Sook Lee,[...]. Clin Cancer Res 2020
34


Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trial.
Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy,[...]. Lancet Oncol 2019
149

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
4

Efficacy and safety of crizotinib in patients with ROS1 rearranged non-small cell lung cancer: a retrospective analysis.
Ken Masuda, Yutaka Fujiwara, Yuki Shinno, Takaaki Mizuno, Jun Sato, Ryo Morita, Yuji Matsumoto, Shuji Murakami, Yasushi Goto, Shintaro Kanda,[...]. J Thorac Dis 2019
6

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
3

Emerging Targeted Therapies for the Treatment of Non-small Cell Lung Cancer.
Patrick R Halliday, Collin M Blakely, Trever G Bivona. Curr Oncol Rep 2019
53